Crotamiton is a drug that is used both as a scabicidal (for treating scabies) and as a general antipruritic (anti-itching drug). It is a lotion-based medicine that is applied to the whole body to get rid of the scabies mite that burrows under the skin and is typically formulated as a 10 percent topical preparation for adult use; the molecule is comparatively lipophilic which favors stratum corneum penetration, shows low to moderate percutaneous absorption, is metabolized hepatically with renal excretion of metabolites, and produces antipruritic and mite-toxic effects with a favorable local tolerability profile when used as directed. Clinical and formulation practice varies by product and region, so dosing intervals, contact time and the need for repeat application follow local product labeling and medical guidance.
Parent: Crotamiton
Active pharmaceutical ingredient specifications are commonly set to ensure high purity and predictable safety; a typical API specification requires assay by validated HPLC of not less than 98.0 percent crotamiton on a dried basis. Individual related organic impurities are often limited to 0.2 percent or less each, with the sum of related impurities not to exceed 1.0 percent, and specified degradation products such as N-dealkylated and hydroxylated crotamiton derivatives and oxidative products monitored by stability-indicating methods. Residual solvents used in manufacture are controlled per ICH Q3C limits, commonly with ethanol or isopropanol reported at low single-digit ppm to under 0.5 percent w/w in finished lotion, and heavy metals and elemental impurities are restricted to pharmacopeial limits, for example individual metals usually below 10 to 20 ppm. Analytical control typically uses HPLC for assay and related substances, GC for residual solvents, and ICP-MS or equivalent for elemental impurities.
Crotamiton is used topically to treat scabies infestations and to relieve generalized itching; as a scabicidal it targets mites in the skin, and as an antipruritic it reduces itch sensations when applied according to product labeling.
No. Hydrocortisone is a topical corticosteroid that reduces inflammation and immune-mediated itching, while crotamiton is not a steroid; crotamiton acts primarily as a topical antipruritic and scabicidal agent and does not have the anti-inflammatory steroid class pharmacology of hydrocortisone.
No. Crotamiton is not an antihistamine in the pharmacologic sense; it does not act as a histamine receptor antagonist. Its antipruritic effects are achieved through local pharmacologic actions distinct from systemic or topical antihistamines.
The precise mechanism is not completely defined; crotamiton exerts scabicidal activity by direct toxic effects on the mite and reduces pruritus through local actions in the skin. The antipruritic effect appears to be peripheral and not dependent on histamine receptor blockade, and systemic pharmacology is limited due to low topical absorption.
